Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + bevacizumab
- Development stage
- Phase 4
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This drug is a combination therapy consisting of **iparomlimab**, **tuvonralimab**, and **bevacizumab**. Iparomlimab is an anti-PD-1 monoclonal antibody, tuvonralimab is an anti-CTLA-4 monoclonal antibody (the combination of the two is also referred to as QL1706), and bevacizumab is a VEGF inhibitor. This combination is studied for its anti-tumor activity in various advanced cancers, including immune-resistant melanoma, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer, hepatocellular carcinoma, and recurrent/metastatic cervical cancer. The regimen targets the immune checkpoint pathways to enhance anti-tumor immunity (PD-1 and CTLA-4 blockade) and inhibits angiogenesis by blocking vascular endothelial growth factor (VEGF). Key developers and sponsors include Qilu Pharmaceutical and clinical sites across China. Clinical trials are ongoing, with multiple phase II studies evaluating efficacy and safety in different malignancies[1][2][3][5][6].
- Brand names
- Qiule
- Other names
- QL1706 + bevacizumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + bevacizumab.